Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Observational

Evaluation of Positron Emission Tomography (PET) With [18F]FET for the Detection of ACTH-Secreting Corticotroph Pituitary Neuroendocrine Tumors.

NCT07463625 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2023-11-23
Last updated
2026-03-11

Condition(s) studied

Cushing DiseaseACTH-producing Pituitary Tumour

Investigational drug(s) / intervention(s)

Data-only evaluation of [18F]FET PET, pituitary MRI, and biomarkers

Data-only evaluation of [18F]FET PET, pituitary MRI, and biomarkers: No study-specific procedures. The study evaluates existing \[18F\]FET PET imaging pituitary MRI, and routine biochemical markers collected as part of standard care.

Study summary

Cushing's disease results from adrenocorticotropic hormone (ACTH) secretion by corticotroph pituitary neuroendocrine tumors (PitNETs). Magnetic resonance imaging (MRI) is the reference modality for etiological diagnosis but may to visualize small corticotroph microadenomas in up to 30% of the cases, and false positives may occur.

The study hypothesis is that positron emission tomography (PET) using \[18F\]fluoroethyl-L-tyrosine (\[18F\]FET) improves localization of ACTH-secreting corticotroph microadenomas compared with MRI and could inform surgical planning and reduce reliance on invasive inferior petrosal sinus sampling.

This observational cohort (retrospective and prospective data) will assess the diagnostic performance of \[18F\]FET PET for tumor localization using postoperative histopathology as the gold standard.

Secondary aims include:

1. assessing cases in which PET modifies localization relative to MRI and is correct by gold standard;
2. inter-reader agreement between two nuclear medicine physicians;
3. correlations between PET signal and biochemical markers of hypercortisolism
4. uni- and multivariable analyses of clinical and imaging parameters influencing PET results;
5. association between PET findings and subsequent biological remission.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adults (≥18 years). * Biochemical diagnosis of Cushing's disease as part of initial management. * Pituitary MRI performed; if visible, microadenoma \<10 mm in diameter. * Indication for discussion in multidisciplinary tumor board for surgical management. Exclusion Criteria: * Minor (age \<18 years). * Macroadenoma of the pituitary. * ACTH-dependent hypercortisolism secondary to ectopic secretion.

Primary outcome measure(s)

  • [18F]FET PET Performance for Localizing Corticotroph Pituitary Adenomas — 3 months
    Proportion (%) of correct localization of the adenoma by \[18F\]FET PET, using postoperative histopathological examination of the surgical specimen as the reference standard.

Trial sites (1)

FacilityCityRegionStatus
Hôpital Louis Pradel - Service de Médecine Nucléaire Bron France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07463625 on ClinicalTrials.gov ↗ ← All trials in France